Six-Month Response to Delamanid Treatment in MDR TB Patients

Details

• Alternative Title:
  Emerg Infect Dis
• Personal Author:
  Hewison, Cathy ; Ferlazzo, Gabriella ; Avaliani, Zaza ; Hayrapetyan, Armen ; Jonckheere, Sylvie ; Khaidarkhanova, Zarema ; Mohr, Erika ; Sinha, Animesh ; Skrahina, Alena ; Vambe, Debrah ; Vasilyeva, Irina ; Lachenal, Nathalie ; Varaine, Francis
• Description:
  Delamanid, recently available for the treatment of multidrug-resistant tuberculosis (MDR TB), has had limited use outside clinical trials. We present the early treatment results for 53 patients from 7 countries who received a delamanid-containing treatment for MDR TB. Results show good tolerability and treatment response at 6 months.
• Subjects:
  Adolescent Antitubercular Agents Female Hepatitis C Hiv Infections Humans Male Nitroimidazoles Oxazoles Retrospective Studies Tuberculosis, Multidrug-Resistant

  More +
• Source:
  Emerg Infect Dis. 23(10):1746-1748.
• Pubmed ID:
  28767036
• Pubmed Central ID:
  PMC5621551
• Document Type:
  Letter
• Place as Subject:
  Armenia ; Belarus ; Georgia (Republic) ; India ; Russia ; South Africa ; Swazilad
• Volume:
  23
• Issue:
  10
• Collection(s):
  Emerging Infectious Diseases
• Main Document Checksum:
  urn:sha256:a7b3306b618f2ce8a20f1756a7f4d948f42e7fc4feb0652462002a3436ab6a85
• Download URL:
  https://stacks.cdc.gov/view/cdc/48986/cdc_48986_DS1.pdf
• File Type:
  [PDF - 336.63 KB ]